Britain and America have announced a key bilateral deal that will guarantee zero tariffs on British drug shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the public health system. This move guarantees that import taxes on these key exports will be held at zero for a duration of the next three years.
This agreement is in response to earlier statements to dramatically increase import taxes on patented drug products, with potential rates discussed reaching double the cost.
"This arrangement with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. drug exports," a release said.
Economic Significance
Medicines constitute one of the the United Kingdom's biggest export categories to the United States, which is by far the primary buyer for major UK drugmakers.
Trade data show that in the 12 months prior to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up a significant portion of all goods exports in that span.
"This deal safeguards work, boosts investment and facilitates the UK to emerge as a international leader for life sciences," a minister commented.
Key UK Commitments
The agreement includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to double overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates were more than 20%.
Industry Background
This agreement comes amid a protracted row between the sector and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by arguments that US consumers were paying a premium for the same drugs than people in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
